July 26th 2024
Findings from the phase 2 NeoPembrOV study supported the addition of pembrolizumab to neoadjuvant chemotherapy before surgery in high-grade serous ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Phase 1 Study Shows Signals of Response With Vaccine for HPV16+ Premalignancies
December 1st 2022In a phase 1 study, a peptide conjugated vaccine showed potent immunogenicity and was able to induce functional T-cell responses in almost all vaccinated patients with HPV16-positive premalignancies.
Read More
Salani Reviews Role of PARP Inhibition in Ovarian Cancer
November 24th 2022During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.
Read More
FDA Approves Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer
November 14th 2022Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.
Read More
The Role of Rucaparib in Ovarian Cancer Following the ARIEL4 Readout
October 22nd 2022In an interview with Targeted Oncology™, Amit M. Oza, MD, discussed the overall survival analysis of the ARIEL4 clinical trial and unanswered questions about rucaparib treatment in certain ovarian cancer subgroups.
Read More
The Role of Biomarker Testing in Ovarian Cancer
October 17th 2022There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.
Read More
Further Research Needed to Improve Outcomes in Advanced Ovarian Cancer
October 4th 2022Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.
Watch
OnPrime Study of Olvi-Vec, Platinum-Doublet, and Bevacizumab Initiates in Ovarian Cancer
September 26th 2022Based on preclinical studies which have shown the clinical benefit of Olvi-Vec, a phase 3 trial evaluating the agent in combination with platinum-doublet chemotherapy and bevacizumab has commenced in patients with platinum-resistant/refractory ovarian cancer.
Read More
Weekly Dose-Dense Paclitaxel Not Recommended as Standard Therapy for 1L Ovarian Cancer
July 29th 2022Mature survival data from the phase 3 ICON8 trial revealed no significant difference between administering weekly dose-dense chemotherapy and standard 3-weekly chemotherapy as front-line therapy for patients with epithelial ovarian cancer.
Read More
Key Takeaways from the OUTBACK Trial of Adjuvant Chemotherapy in Cervical Cancer
July 23rd 2022Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.
Watch
Ofra-vec/Paclitaxel Shows No Significant Survival Benefit in Platinum-Resistant Ovarian Cancer
July 20th 2022The phase 3 OVAL clinical trial has been discontinued after the combination of ofranergene obadenovec and paclitaxel did not achieve the study’s primary end points of improvement in progression-free and overall survival.
Read More
Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.
Read More
An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.
Read More
Adjuvant Immunotherapy Combinations Are Explored in Endometrial Cancer
May 20th 2022The benefit of pembrolizumab compared with placebo in combination with adjuvant chemotherapy with or without radiation therapy in patients with newly diagnosed high-risk endometrial cancer after surgery with curative intent is under evaluation in the ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.
Read More
FDA Grants Fast Tracks SQZ-PBMC-HPV for HPV16+ Advanced/Metastatic Solid Tumors
April 28th 2022The FDA has granted fast track designation to SQZ-PBMC-HPV for the treatment of patient with HPV16-positive advanced or metastatic solids tumors, according to an announcement by SQZ Biotechnologies.
Read More